Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) EBITDA
Gilead Sciences, Inc.'s EBITDA for fiscal 2025 was $12.8B, up 188.6% from $4.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $262.0M. Over the past ten years it has ranged from $4.4B (fiscal 2024) to $23.3B (fiscal 2015); the current reading is higher than 73% of that period. Gilead Sciences, Inc. ranks 16th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $12.8B | 188.60% |
| FY2024 | $4.4B | (56.99%) |
| FY2023 | $10.3B | 9.17% |
| FY2022 | $9.4B | (21.18%) |
| FY2021 | $12.0B | 115.60% |
| FY2020 | $5.6B | (2.46%) |
| FY2019 | $5.7B | (40.90%) |
| FY2018 | $9.6B | (37.51%) |
| FY2017 | $15.4B | (17.99%) |
| FY2016 | $18.8B | (19.32%) |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$9.7B | — |
| Mar 2026 | $3.3B | 22.58% |
| Dec 2025 | $2.7B | (33.44%) |
| Sep 2025 | $4.0B | 26.79% |
| 42 more quarters | Free account |
Against its own ten years
Low $4.4B
High $23.3B
Ten-year median
$10.3B
Current reading's percentile
73
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $26.5B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $15.1B |
| GSK GSK PLC Sponsored ADR compare | $12.8B |
| SNY Sanofi compare | $10.4B |
| GILD Gilead Sciences, Inc. | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GILD
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement